The Pharamron-backed oncology drug developer floated at the top of its range while increasing the number of shares in the offering.
Zentalis Pharmaceuticals, a US-based small molecule therapeutics developer backed by research services provider Pharmaron, went public on Friday in a $165m initial public offering on the Nasdaq Global Market.
The company increased the number of shares in the offering from 7.65 million to 9.18 million and priced them at the top of the IPO’s $16 to $18 range. Its shares closed at $23.20 on their first day of trading and have risen to $25.20 at time of publication.
Founded…
